SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is buzzing with conversation after its recent financial update, which showcased impressive membership growth and an optimistic 2026 outlook, fueling bullish enthusiasm despite concerns over a quarterly performance miss and ongoing uncertainty surrounding broader healthcare policy.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid a broad software sector sell-off, fueled by investor concerns that rapidly advancing AI will disrupt or replace traditional SaaS models. While some analysts and market participants argue that AI will enhance core enterprise software and point to a significant government contract, the community remains polarized between those calling it a "generational buying opportunity" and those fearing further valuation compression.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to its strong Q4 earnings beat and robust subscriber growth, alongside recent premium subscription price increases. The community is widely debating if these positive catalysts, coupled with new AI features and video content, can reverse the stock's recent downtrend and its perceived correlation with Netflix's performance, as many consider it oversold.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv (FISV) is actively trending as investors keenly await its earnings report, fueling intense community debate between those who believe the stock is deeply undervalued with a promising turnaround under new leadership, and others bracing for a significant drop mirroring previous disappointments and broader fintech sector headwinds. Significant options activity indicates widespread expectation of a volatile price movement following the announcement.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following strong Q4 earnings and a new share buyback, prompting community debate over its significant stock-based compensation and dilutive practices, particularly as reports circulate about Meta's Instagram developing a rival app.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending after the FDA issued a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns over trial design and efficacy evidence, compounding worries from an earlier clinical hold related to a brain tumor in a related gene therapy. The community is actively debating the severe financial implications of this setback, exacerbated by multiple downgrades, though some hold hope for other pipeline assets like the AbbVie-partnered RGX-314.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is gaining significant traction following bullish analyst initiations, with firms like Cantor Fitzgerald labeling it the "Amazon of Africa" and setting an $18 price target. This momentum, combined with strong Q4 sales and expectations for imminent profitability, is fueling community excitement around its long-term potential in Africa's rapidly expanding e-commerce market.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending after securing crucial Medicare coverage for its ultra-sensitive Molecular Residual Disease (MRD) test, marking a significant de-risking milestone for the company. The community is highly optimistic about this pivotal step, anticipating substantial revenue growth and further approvals to solidify Personalis's position in the rapidly evolving cancer diagnostics market.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending lower following mixed guidance for the upcoming quarter and fiscal year, despite reporting stronger-than-expected Q4 earnings. This has ignited a contentious debate among investors, with many fearing AI will render its services obsolete, while others view the pullback as a prime buying opportunity, banking on the company's stated focus on human-plus-AI collaboration.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following strong Q4 2025 financial results and positive FY26 guidance, bolstered by recent FDA approvals for its oncology blockbusters Enhertu and Datroway, and groundbreaking Phase 3 data for hypertension treatment Baxdrostat. The community is actively discussing the company's strategic direct listing on the NYSE, along with significant investments in US manufacturing and an expanding obesity pipeline in China, all signaling a robust long-term growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mark Schoenberg Sells 7,373 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 7,373 shares of the business's stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of...

Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages

Urogen Pharma (NASDAQ:URGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat reports. One...

Privium Fund Management B.V. Increases Stock Position in Urogen Pharma $URGN

Privium Fund Management B.V. lifted its holdings in Urogen Pharma (NASDAQ:URGN - Free Report) by 82.7% during the third quarter, according to its most recent 13F filing with the Securities and...

Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Friday...

Harel Insurance Investments & Financial Services Ltd. Trims Holdings in Urogen Pharma $URGN

Harel Insurance Investments & Financial Services Ltd. decreased its holdings in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 47.5% in the 3rd quarter, according to its most recent Form 13F...

Urogen Pharma (NASDAQ:URGN) Shares Down 6.5% - What's Next?

Urogen Pharma (NASDAQ:URGN) Stock Price Down 6.5% - Time to Sell...

D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN)

D. Boral Capital restated a "buy" rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Monday...

Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC raised its position in Urogen Pharma (NASDAQ:URGN - Free Report) by 187.8% during the second quarter, according to the company in its most recent 13F filing with the Securities...

Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 20,427 call options on the company. This represents an...

Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4% - Still a Buy?

Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4% - Still a Buy...

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Pharma Ltd

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$21.90
Prev Close	$21.35
Open	$21.24
Dividend Yield	0.00%
50-Day Moving Average	$22.36
Beta	1.12
Avg. Volume	728,235.45
PE Ratio	-6.17

52-Week High	$30.00
52-Week Low	$3.42
Market Capitalization	$999.37M
EPS (Annual)	-$2.96
Price to Book	-8.65
Revenue Per Employee	$384,672.34
Enterprise Value/EBITDA	N/A

URGN
UroGen Pharma Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest URGN News

URGNUroGen Pharma Ltd